<DOC>
	<DOCNO>NCT01032070</DOCNO>
	<brief_summary>This phase 2 study evaluate efficacy single-agent erlotinib versus oral etoposide patient recurrent refractory pediatric ependymoma .</brief_summary>
	<brief_title>Erlotinib Versus Oral Etoposide Patients With Recurrent Refractory Pediatric Ependymoma</brief_title>
	<detailed_description>This phase 2 study involve 1:1 randomization 40 patient recurrent refractory pediatric ependymoma receive either erlotinib oral etoposide .</detailed_description>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Recurrent refractory ependymoma subependymoma Performance Status ( PS ) : Lansky ≥ 50 % patient ≤ 10 year age Karnofsky ≥ 50 % patient &gt; 10 year age Measurable disease , define 1 measurable lesion accurately measure 2 plane receive radiation therapy within 12 week Recovered acute toxic effect prior chemotherapy , immunotherapy , radiotherapy ≥ 1 year ≤ 21 year Serum creatinine patient ≤ 5 year age ≤ 0.8 mg/dL Creatinine Clearance/Glomerular Filtration Rate ( GFR ) ≥ 70 mL/min/m^2 Serum creatinine patient &gt; 5 ≤ 10 year age ≤ 1.0 mg/dL Creatinine Clearance/GFR ≥ 70 mL/min/m^2 Serum creatinine patient &gt; 10 ≤ 15 year age ≤ 1.2 mg/dL Creatinine Clearance/GFR ≥ 70 mL/min/m^2 Serum creatinine patient &gt; 15 year age ≤ 1.5 mg/dL Creatinine Clearance/GFR ≥ 70 mL/min/m^2 Total bilirubin ≤ 1.5 x upper limit normal age Alanine aminotransferase ( ALT ) ≤ 3 x upper limit normal Absolute neutrophil count &gt; 1000/µL Platelet count &gt; 100,000/µL Hemoglobin &gt; 8 gm/dL Neurologically stable least 7 day prior randomization If receiving corticosteroid , patient must stable decrease dose least 7 day randomization Patients reproductive potential must agree proactive effective contraceptive measure duration study least 90 day completion study drug Previously receive epidermal growth factor receptor ( EGFR ) target therapy Previously receive oral etoposide Received craniospinal radiotherapy within 24 week prior randomization Received field radiotherapy target lesion within 12 week prior randomization Received symptomatic metastatic disease within 14 day prior randomization Received myelosuppressive chemotherapy within 21 day randomization Received growth factor within 7 day prior randomization Participating another investigational drug trial Received biologic agent within 7 day prior randomization Received monoclonal antibody within 28 day prior randomization Taking cytochrome P450 ( CYP ) 3A4 CYP1A2 inhibitors/inducers within 14 day prior randomization Taking proton pump inhibitor within 14 day prior randomization Smoking treatment Pregnant breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>phase 2</keyword>
	<keyword>erlotinib</keyword>
	<keyword>pediatric</keyword>
	<keyword>etoposide</keyword>
	<keyword>ependymoma</keyword>
</DOC>